 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. NASDAQ: ADMS to Supernus Pharmaceuticals, Inc. for 8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to 1.00 per share in cash is fair to Adamas shareholders. Halper Sadeh encourages Adamas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halpe 